Lantheus Holdings Inc (LNTH, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Lantheus Holdings Inc develops diagnostic products for the healthcare sector. Its chief product is imaging agents used by physicians in diagnostic procedures such as cardiac ultrasounds and X-ray imaging. Lantheus Holdings Inc has a market cap of $847.370 million; its shares were traded at around $22.03 with a P/E ratio of 6.83 and P/S ratio of 2.59. Lantheus Holdings Inc had annual average EBITDA growth of 33.30% over the past five years.
For the last quarter Lantheus Holdings Inc reported a revenue of $88.9 million, compared with the revenue of $79.94 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $343.4 million, an increase of 3.6% from last year. For the last five years Lantheus Holdings Inc had an average revenue growth rate of 3.7% a year.
The reported diluted earnings per share was $1.03 for the year, a decline of 67.5% from the previous year. The Lantheus Holdings Inc had a decent operating margin of 18.78%, compared with the operating margin of 15.65% a year before. The 10-year historical median operating margin of Lantheus Holdings Inc is 13.07%. The profitability rank of the company is 5 (out of 10).
At the end of the fiscal year, Lantheus Holdings Inc has the cash and cash equivalents of $113.4 million, compared with $76.3 million in the previous year. The long term debt was $263.7 million, compared with $265.4 million in the previous year. The interest coverage to the debt is 3.7. Lantheus Holdings Inc has a financial strength rank of 5 (out of 10).
At the current stock price of $22.03, Lantheus Holdings Inc is traded at 75% premium to its historical median P/S valuation band of $12.59. The P/S ratio of the stock is 2.59, while the historical median P/S ratio is 1.46. The stock gained 7.46% during the past 12 months.
CEO Recent Trades:
- President & CEO Mary Anne Heino sold 9,564 shares of LNTH stock on 01/30/2019 at the average price of $16.47. The price of the stock has increased by 33.76% since.
Directors and Officers Recent Trades:
- Chief Medical Officer Cesare Orlandi sold 4,057 shares of LNTH stock on 02/06/2019 at the average price of $18.06. The price of the stock has increased by 21.98% since.
- See Remarks Michael P Duffy sold 7,651 shares of LNTH stock on 01/31/2019 at the average price of $16.48. The price of the stock has increased by 33.68% since.
- Chief Medical Officer Cesare Orlandi sold 3,060 shares of LNTH stock on 01/31/2019 at the average price of $16.56. The price of the stock has increased by 33.03% since.
For the complete 20-year historical financial data of LNTH, click here.
